prof. dr. W. (Wijnand) Helfrich

E-mail:
w.helfrich umcg.nl

Research

Publications
  1. Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade

    Koopmans, I., Hendriks, M. A. J. M., van Ginkel, R. J., Samplonius, D. F., Bremer, E. & Helfrich, W., 23-May-2019, In : Journal of Investigative Dermatology. 39 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Targeting the messengers of death: the advent of selective activation of apoptosis for cancer therapy.

    Bremer, E. & Helfrich, W., 1-Jan-2006, In : Discovery medicine. 6, 33, p. 113-117 5 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy

    He, Y., Helfrich, W. & Bremer, E., 2019, Cancer Immunosurveillance: Methods and Protocols. Humana Press, p. 335-347 13 p. (Methods in Molecular Biology).

    Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

  4. Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition

    de Boer, H. R., Pool, M., Joosten, E., Everts, M., Samplonius, D. F., Helfrich, W., Groen, H. J. M., van Cooten, S., Fusetti, F., Fehrmann, R. S. N., de Vries, E. G. E. & van Vugt, M. A. T. M., 28-Feb-2019, In : ONCOGENE. 38, 9, p. 1477-1488 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (105) »

View graph of relations

ID: 82686